title: Market watch: Upcoming catalysts in Q2 2015.
authors.affiliation: Sagient Research Systems, 3655 Nobel Drive, San Diego, California 92122, USA.
authors.forename: Justin
authors.initials: J
authors.lastname: Burns
mesh_terms: D000813:Anilides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D017277:Drug Approval; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D000077594:Nivolumab; D011725:Pyridines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000813:Anilides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011725:Pyridines; C546027:elotuzumab; C558660:cabozantinib; D000077594:Nivolumab; D020794:Receptor Protein-Tyrosine Kinases